{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T04:03:40Z","timestamp":1748837020321,"version":"3.41.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jtct.2024.03.025","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T09:02:22Z","timestamp":1711530142000},"page":"607.e1-607.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunosuppression-Free Status at 1 Year after Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3766-5623","authenticated-orcid":false,"given":"Melhem","family":"Solh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asad","family":"Bashey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Kent","family":"Holland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizamarie","family":"Bachier-Rdriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence E.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2061-8126","authenticated-orcid":false,"given":"Scott R.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2024.03.025_bib0001","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/bmt.2015.195","article-title":"Physical function and quality of life in patients with chronic GvHD: a summary of preclinical and clinical studies and a call for exercise intervention trials in patients","volume":"51","author":"Fiuza-Luces","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.03.025_bib0002","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1158\/1078-0432.CCR-14-0586","article-title":"Impact of chronic graft-versus-host disease on late relapse and survival on 7,489 patients after myeloablative allogeneic hematopoietic cell transplantation for leukemia","volume":"21","author":"Boyiadzis","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2024.03.025_bib0003","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","article-title":"Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation","volume":"125","author":"Holtan","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.03.025_bib0004","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.bbmt.2016.04.006","article-title":"Factors predicting graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation: multivariable analysis from a single center","volume":"22","author":"Solh","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.03.025_bib0005","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1200\/JCO.19.00396","article-title":"Composite GRFS and CRFS outcomes after adult alternative donor HCT","volume":"38","author":"Mehta","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2024.03.025_bib0006","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3324\/haematol.2015.138990","article-title":"Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults","volume":"101","author":"Mehta","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2024.03.025_bib0007","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2024.03.025_bib0008","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.03.025_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current use of and trends in hematopoietic cell transplantation in the United States","volume":"26","author":"D'Souza","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.03.025_bib0010","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8868142","article-title":"A phase II trial of melphalan-based reduced-intensity conditioning for transplantation of T-replete HLA-haploidentical peripheral blood stem cells with posttransplant cyclophosphamide in patients with hematologic malignancies","volume":"2021","author":"Solh","year":"2021","journal-title":"Adv Hematol"},{"key":"10.1016\/j.jtct.2024.03.025_bib0011","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.bbmt.2015.03.003","article-title":"Total body irradiation-based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors","volume":"21","author":"Solomon","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.03.025_bib0012","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2017.72.8428","article-title":"Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell-replete haploidentical donor transplantation using post-transplant cyclophosphamide","volume":"35","author":"Bashey","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2024.03.025_bib0013","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.bbmt.2012.06.019","volume":"18","author":"Solomon","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.03.025_bib0014","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.03.025_bib0015","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.03.025_bib0016","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.bbmt.2020.07.035","article-title":"Differences in graft-versus-host disease characteristics between haploidentical transplantation using post-transplantation cyclophosphamide and matched unrelated donor transplantation using calcineurin inhibitors","volume":"26","author":"Solh","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.03.025_bib0017","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood.2021013443","article-title":"HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide","volume":"139","author":"Fuchs","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.03.025_bib0018","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1053\/j.seminhematol.2016.08.001","article-title":"Selecting the best haploidentical donor","volume":"53","author":"McCurdy","year":"2016","journal-title":"Semin Hematol"},{"key":"10.1016\/j.jtct.2024.03.025_bib0019","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood-2014-03-563130","article-title":"Who is the best donor for a related HLA haplotype-mismatched transplant?","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.03.025_bib0020","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/bloodadvances.2017014829","article-title":"Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide","volume":"2","author":"McCurdy","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2024.03.025_bib0021","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/leu.2014.336","article-title":"A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia","volume":"29","author":"Piemontese","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2024.03.025_bib0022","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2015-01-623991","article-title":"Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide","volume":"125","author":"McCurdy","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.03.025_bib0023","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.bbmt.2014.12.018","article-title":"Can a female donor for a male recipient decrease the relapse rate for patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation?","volume":"21","author":"Kongtim","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.03.025_bib0024","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1399-0039.1997.tb02801.x","article-title":"African-American HLA class II allele and haplotype diversity","volume":"49","author":"Just","year":"1997","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.jtct.2024.03.025_bib0025","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1056\/NEJMsb025007","article-title":"The importance of race and ethnic background in biomedical research and clinical practice","volume":"348","author":"Burchard","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2024.03.025_bib0026","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ajh.23594","article-title":"Effect of race on outcomes after allogeneic hematopoietic cell transplantation for severe aplastic anemia","volume":"89","author":"Eckrich","year":"2014","journal-title":"Am J Hematol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724002999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724002999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T05:28:02Z","timestamp":1748755682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724002999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2666636724002999"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.03.025","relation":{},"ISSN":["2666-6367"],"issn-type":[{"type":"print","value":"2666-6367"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunosuppression-Free Status at 1 Year after Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.03.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}